This inventor holds 2 USPTO granted patents. Top assignees: Max-Delbruck-Centrum Fur Molekulare Medizin, Max-Delbrueck-Centrum Fuer Molekulare Medizin. Active years: 2015-2016.
Company Filing History:
1 out of 32 
1 out of 18 Years Active: 2015-2016
Title: Franziska Schiele: Innovator in Protein Modulation
Introduction
Franziska Schiele is a prominent inventor based in Rottenburg am Neckar, Germany. She has made significant contributions to the field of molecular medicine, particularly in the modulation of protein processing and aggregation. With a total of 2 patents, her work focuses on addressing critical health issues related to protein misfolding and neurodegenerative disorders.
Latest Patents
Franziska's latest patents include innovative compounds aimed at enhancing protein degradation. The first patent relates to compounds suitable for modulating huntingtin protein processing, which are useful for treating or preventing huntingtin-related disorders. This invention provides pharmaceutical compositions comprising these compounds and methods of synthesis. The second patent involves azo compounds that reduce the formation and toxicity of amyloid beta aggregation intermediates. These compounds serve as modulators of protein misfolding and aggregation, particularly as inhibitors of amyloid aggregate formation and as activators of degradation or reduction of amyloid aggregates.
Career Highlights
Throughout her career, Franziska has worked with esteemed institutions such as the Max Delbrück Center for Molecular Medicine. Her research has significantly advanced the understanding of protein dynamics and their implications in various diseases.
Collaborations
Franziska has collaborated with notable scientists, including Erich Wanker and Thomas Wiglenda. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.
Conclusion
Franziska Schiele's contributions to the field of molecular medicine through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in treating neurodegenerative disorders.